Aquestive Therapeutics Q1 2024 GAAP EPS $(0.17) Misses $(0.07) Estimate, Sales $12.053M Miss $12.262M Estimate
Aquestive Therapeutics Q1 2024 GAAP EPS $(0.17) Misses $(0.07) Estimate, Sales $12.053M Miss $12.262M Estimate
Aquestive Therapeutics2024年第一季度GAAP每股收益美元（0.17美元）未達到預期（0.07美元），銷售額爲1,205.3萬美元，未達到1226.2萬美元的預期
Aquestive Therapeutics (NASDAQ:AQST) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.07) by 142.86 percent. This is a 254.55 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $12.053 million which missed the analyst consensus estimate of $12.262 million by 1.71 percent. This is a 8.25 percent increase over sales of $11.134 million the same period last year.
Aquestive Therapeutics（納斯達克股票代碼：AQST）公佈的季度虧損爲每股0.17美元，比分析師普遍預期的0.07美元（0.07美元）低142.86％。與去年同期的每股收益0.11美元相比，下降了254.55％。該公司公佈的季度銷售額爲1,205.3萬美元，比分析師普遍預期的1226.2萬美元低1.71％。這比去年同期的1113.4萬美元的銷售額增長了8.25％。